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Chronic pain affects approximately 20% of the adult population in 
Europe, with up to two-thirds of patients reporting dissatisfaction 
with current therapies.1 Patients often receive complex treatment 
plans that combine pharmacological and non-pharmacological ap-
proaches. The limited understanding of basic underlying mecha-
nisms and their complex interplay involved in the pathophysiol-
ogy has led to chronic pain remaining a significant unmet medical 
need. Current therapeutic approaches for chronic pain often do not 
provide adequate relief and, because the central nervous system 
(CNS) is the location of many drug targets, various central side ef-
fects are often experienced by patients.2 As new ideas for analgesic 
drug design are urgently needed, the biological processes responsi-
ble for chronic pain have been the focus of preclinical research to 
identify potential targets for drug discovery.
Flupirtine, a selective neuronal potassium channel opener and 
non-opioid analgesic, has exhibited pain relieving activity in vari-
ous animal models and humans without anti-inflammatory or anti-
pyretic properties.3–5 Flupirtine was synthesized and first approved 
in Germany in the 1980s and is a triaminopyridine derivative 
with the chemical structure of 2-amino-3-ethoxy-carbonylamino-
6-4-fluoro-benzylamino-pyridine. Flupirtine exhibits indirect N-
methyl-D-aspartate (NMDA) receptor antagonism via activation of 
potassium channels, leading to the suppression of neuronal overex-
citability.3,4 Thus, flupirtine has been used as an analgesic for the 
last 35 years in the management of pain and also exerts skeletal 
muscle relaxation and neuroprotection properties.3–5 Flupirtine is 
available as the maleate salt, a hydrophilic compound that is rap-
idly absorbed from the gastrointestinal tract with a bioavailability 
of 90%.6,7 The volume of distribution (Vd) of 100 mg of flupirtine 
is 154 L in healthy volunteers and is up to 84% bound to human 
albumin.6,7 The half-life of flupirtine depends on the route of ad-
ministration, but is typically between 6.5–10.7 h. Following oral 
administration of 100 mg of flupirtine, clearance is 275 ml/min in 
healthy volunteers.6,7 Flupirtine is metabolized in the liver by per-
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Fibromyalgia is a complex disorder characterised by chronic pain, fatigue, sleep disturbance and cognitive dys-
function with limited benefit gained with current therapies. The mean global prevalence of 2.7% is estimated for 
this chronic condition. Pharmacological and non-pharmacological therapeutic approaches are often required as 
treatments of the challenges associated with fibromyalgia. Flupirtine, a non-opioid drug, exhibits effective anal-
gesia in a range of acute and persistent pain conditions, and evidence as treatment of fibromyalgia is considered. 
Activation of Kv7 potassium channels and agonism at gamma-aminobutyric acid receptor A leading to indirect 
N-methyl-D-aspartate receptor antagonism is responsible for the analgesic effects of flupirtine and appears to be 
involved in other symptoms associated with fibromyalgia. Patients with fibromyalgia reported improved control 
of their symptoms without significant adverse effects in an observational audit in clinical practice. This article 
presents evidence that flupirtine, or related drugs, is a therapeutic option for the treatment of fibromyalgia. The 
pharmacology of flupirtine and mechanisms of action involved provide a spectrum of effects that would not only 
control the chronic pain characteristic of fibromyalgia but many of the other symptoms. Thus, further investiga-
tion of the efficacy of flupirtine or related drugs exhibiting a similar pharmacology as a treatment of fibromyalgia 
would be of interest.
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oxidase enzymes to the active N-acetylated analogue D13223 and 
4-fluorohippuric, which are further oxidised and then conjugated 
to inactive metabolites. The most common adverse effects, which 
occurred within 6 months of treatment and are dose dependent, 
are dizziness, drowsiness, pruritis, dry mouth, gastric discomfort, 
nausea and muscle tremor.3–5
This article will consider the potential of flupirtine as a treat-
ment for the chronic pain condition fibromyalgia. Relevant stud-
ies and publications have been identified using the search terms 
flupirtine and chronic pain in the literature databases MEDLINE, 
Web of Science, The Cochrane Library (Cochrane Database of 
Systematic Reviews, Cochrane Central Register of Controlled Tri-
als (CENTRAL), Cochrane Methodology Register) and Google 
Scholar. In addition, evidence from a clinical observational audit 
is considered.
Fibromyalgia
Chronic widespread pain is a primary characteristic of fibromyal-
gia, with the accompaniment of fatigue, disturbed sleep and cogni-
tive issues.8,9 The four main types of pain are nociceptive, inflam-
matory, neuropathic and functional. Nociceptive pain is associated 
with tissue damage, whilst inflammatory pain is associated with 
an inflammatory response. Neuropathic pain is caused by nerve 
irritation or damage and functional pain is pain without an obvious 
cause. The pain experienced with fibromyalgia is characterized 
by reduced pressure pain thresholds with hyperalgesia and allo-
dynia. Fibromyalgia has been classified by the American College 
of Rheumatology (ACR) 1990 criteria of widespread pain (for at 
least 3 months) in all four quadrants of the body and pain in 11 of 
18 tender point sites.10 Revisions were introduced in 2010 to avoid 
reliance on use of tender points in assessment and to reflect the 
range of symptoms by including the assessment of somatic symp-
tom severity (sleep disturbance, cognitive disturbance and fatigue) 
and widespread pain.11 The use of a fibromyalgia symptom scale 
to avoid potential misclassification of patients was the basis of fur-
ther revision in the 2016 criteria.12 The prevalence of fibromyalgia 
is 0.4–8% of the worldwide population, with a greater incidence of 
diagnosis in females than males.9,13 The presence of co-morbidi-
ties exhibiting similar symptoms, e.g. chronic fatigue syndrome, 
often complicates the diagnosis of fibromyalgia.
Neuronal excitability due to amplified responses of the CNS 
to peripheral input has led to central sensitization (CS) being pro-
posed to be involved in the pathophysiology of fibromyalgia (Fig. 
1).9 Peripheral sensory generators, including nerve pathologies, 
neuro-inflammation, skeletal muscle abnormalities and ischaemia, 
evoke heightened activity of the CNS leading to the symptoms of 
fibromyalgia.14,15 Altered neurotransmitter functioning and possi-
ble neuroplasticity has been suggested to lead to the augmented 
sensory processing by the CNS.14 Further, systemic stress-related 
effects, such as alterations in the hypothalamic pituitary adrenal 
axis, the autonomic nervous system and cardiovascular system, are 
also proposed to contribute to the symptoms of fibromyalgia.9,14
As with many chronic pain conditions, pharmacological and 
non-pharmacological therapeutic approaches are often used in the 
treatment of fibromyalgia.8 The focus of drug therapies is often to-
wards the treatment of pain by lowering levels of pro-nociceptive 
excitatory neurotransmission or/and increasing anti-nociceptive 
neuro-transmission rather than treating the overall condition.8 
An altered biochemistry in fibromyalgia is consistent with the 
decreased activity of the descending serotonergic-noradrenergic 
efferent pathways responsible for an aberrant diffuse noxious in-
hibitory control (DNIC).9,14 Thus, current therapeutic options for 
fibromyalgia may modulate serotonin and noradrenaline levels, or 
act on voltage-gated calcium channel subunits.9 Although a few 
drugs have exhibited efficacy in the management of fibromyalgia 
symptoms, the outcomes are limited with only a proportion of pa-
tients experiencing a partial reduction of symptom severity, often 
only marginally better than placebo.16,17 The incidence of adverse 
effects leading many patients to discontinue use further limits the 
effectiveness of current medications.16,17 Thus, no definitive treat-
Fig. 1. Pathophysiology of fibromyalgia. Amplified neuronal excitability within the central nervous system associated with activation of peripheral genera-
tors leads to central sensitization. Altered biochemistry and neurotransmitter levels are linked to the symptoms of fibromyalgia. Raised biochemical levels 
are indicated by an upward facing arrow and lowered biochemical are indicated by a downward facing arrow. CSF, cerebrospinal fluid.
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ment or treatment algorithm exists with management guidelines 
indicating individualised approaches.12
Elevated glutamate, glutamine and glycine levels in pain-re-
lated brain regions, such as the posterior insula and cerebrospinal 
fluid, which correlate to the levels in pain in fibromyalgia, have 
been reported in brain spectroscopy studies.18,19 Thus, in this pa-
tient group, NMDA receptors in the spinal cord and brain are ex-
posed to raised levels of glutamate. Several drugs that downregu-
late NMDA receptors, such as ketamine, dextromethorphan and 
memantine, reduce fibromyalgia-related symptoms.20 Drugs used 
in the management of fibromyalgia, such as gabapentin, pregaba-
lin and certain antidepressants, reduce glutamate levels and may 
evoke an indirect effect on NMDA receptor activation.21,22
Flupirtine as a treatment of pain
Effective analgesia has been reported in a range of acute and 
chronic pain conditions, such as musculoskeletal pain, postopera-
tive pain, migraine and neuralgia following treatment with flupir-
tine.5,23,24 Restoration of the normal sensitivity of over-excitable 
nociceptive pathways and inhibition of the stimulation of nocic-
eptive neurons by factors such as inflammatory mediators (e.g. 
bradykinin) have been suggested to be responsible for the effects 
of flupirtine.25,26 In a post-marketing surveillance study of 7,806 
patients, flupirtine (200–300 mg/day) exhibited effective analgesia 
after four weeks in more than 95% of patients with acute, subacute 
and chronic pain.27 Clinically relevant improvements in quality-
of-life and sleep were also associated in addition to a direct effect 
on pain with flupirtine treatment, where the incidence of adverse 
effects was 0.9% with no serious events reported. Thus, flupirtine 
is well tolerated with mild and infrequent adverse effects.28 Flupir-
tine has been used extensively in clinical practice, as exemplified 
by 28.6 x 106 defined daily doses in Germany in 2010, supporting 
its use as a viable therapeutic treatment.29–31
Short-term flupirtine, 100 mg twice daily, treatment in patients 
undergoing lower limb surgery and gynaecological ambulatory 
surgeries reduced pain levels comparable with, and gave patient 
satisfaction scores similar or superior to, the non-steroidal anti-in-
flammatory drugs (NSAID) piroxicam and ibuprofen.24,32 In both 
studies, there were no serious adverse effects reported with short-
term (up to 5 days) flupirtine treatment. Flupirtine, at 100 mg, was 
reported to be preferable to pentazocine at 50 mg or tramadol at 
50 mg for pain remission in controlled, double-blind clinical trials 
of patients with severe cancer pain.33,34 In an eight day, open-label 
study of palliative care patients with incurable cancer, flupirtine at 
100 to 300 mg, four times daily, reduced pain scores and was as-
sociated with some reduction in opioid use.35 No serious adverse 
effects were observed and 80% of participants continued to take 
flupirtine after the trial with very good pain control until death. 
Flupirtine at 100 mg also evoked comparable efficacy to paraceta-
mol at 1g in treating acute episodic tension-type headache or acute 
attacks of migraine.36,37
A meta-analysis of flupirtine in chronic pain showed that ben-
efits were non-inferior to active comparators (e.g. tramadol, indo-
methacin, chlormezanone and pentazocine).38 Studies of flupirtine 
in chronic pain conditions are summarized in Table 1.38–43 The 
conditions in which flupirtine was used varied significantly but 
were predominantly musculoskeletal in nature, of which lower 
back pain, a commonly associated symptom of patients with fibro-
myalgia, was the most studied chronic pain condition (67.2%). In 
patients with lower back pain, the efficacy of flupirtine was com-
parative with that of tramadol and superior to placebo, whilst the 
incident of treatment-emergent adverse effects and related study 
discontinuations was significantly lower in the flupirtine group 
relative to the tramadol group.39 The incidence of raised liver func-
tion tests (LFTs) was comparable in the flupirtine, tramadol and 
placebo groups. These observations are consistent with a previous 
lower back pain study where comparable efficacy for flupirtine 
and tramadol was observed but the incidence of adverse effects re-
lated to raised LFTs and number of discontinuation post treatment 
were significantly higher in the tramadol group (1% with flupir-
tine vs 15% with tramadol; p < 0.001).40 In an open-label study of 
osteoporosis-related pain (low back pain, neck pain, shoulder-arm 
pain), efficacy of flupirtine was also observed with low reporting 
of adverse effects (2.4% of patients) and withdrawal from the trial 
(1.4% of patients).41 The duration of treatment within these studies 
was short for chronic conditions and extrapolation of the data for 
a condition such as fibromyalgia may be limited. One long-term 
(12-month) treatment study investigated use of flupirtine in pa-
tients with chronic pain secondary to arthrosis or arthritis who had 
been treated with other analgesics (excluding NSAIDs).42 Most of 
the patients showed an improvement in pain intensity following 
flupirtine treatment despite a high drop-out rate, primarily due to 
ineffectiveness or adverse effects of which dizziness was the most 
common and, constipation and vomiting less frequent.
Flupirtine exerts analgesic properties by activation of voltage-
gated potassium channels belonging to the KCNQ Kv7 subfam-
ily evoking hyperpolarization and stabilization of neuronal mem-
branes, which indirectly reduces NMDA receptor activity.5,44,45 
NMDA receptors are a major target in the prevention and treat-
ment of hyper-algesic pain states, thus supporting the use of flu-
pirtine in the treatment of neuropathic pain conditions. Affinity to 
NMDA receptors by flupirtine has not been reported in binding 
studies, supporting an indirect action.46 Peripheral and central no-
ciceptive pathways contain Kv7 channels with expression in cen-
tral terminals of primary afferents and dorsal horn neurons within 
the spinal cord.28,47–49 Key locations of Kv7 channel expression 
in the nociceptive pathway include the thalamus, cerebral cortex 
and spinal cord. After peripheral injury, a decrease in expres-
sion of Kv7 channels in the peripheral nervous system, such as 
Aδ and C fibres, contributes to increased sensory neuron excit-
ability, which would be suppressed by activation of the remain-
ing Kv7 channels.50,51 Thus, enhancing or recovering the activity 
of Kv7 channels would lead to suppression of aberrant neuronal 
activity as observed in persistent pain conditions. Flupirtine has 
also demonstrated agonist properties at the gamma-aminobutyric 
acid receptor A (GABAA), possibly via reinforcement of GABA 
binding.52 Studies have suggested that flupirtine prefers δ-subunit 
containing GABAA receptors over γ-containing GABAA recep-
tors.53 The different subunit compositions define specific pharma-
cological characteristics such that γ2-subunit containing receptors 
are modulated by benzodiazepines, whereas δ-subunits are highly 
sensitive towards neurosteroids (brain-synthesized metabolites of 
ovarian and adrenal cortical steroid hormones).54 These findings 
suggest that the pharmacological properties of flupirtine at GABA 
receptors differ from those of benzodiazepines. Although agonism 
at GABAA receptors is associated with the induction of addictive 
behaviours in certain drugs, such properties have had limited an-
ecdotal reporting for flupirtine.55 Analysis of the database of the 
German Federal Institute for Drugs and Medical Devices (BfArM) 
for the period 1991 to 2013 only revealed 48 reports of flupirtine 
abuse or dependence.56 Further, treatment with flupirtine and de-
velopment of addictive behaviour being de facto causative or mere 
correlation could not be clarified.
Thus, the analgesic activity of flupirtine may be due to a com-
bined action on Kv7 channels and GABAA receptors in pain neu-
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ral circuits. Although flupirtine failed to exhibit affinity for α1- or 
α2-adrenoceptors, or serotonin 5HT1 or 5HT2 stimulation of in-
hibitory brainstem monoaminergic pathways which descend to the 
spinal dorsal horn associated with the diffuse noxious inhibitory 
control (DNIC) has been postulated as a contributory factor for 
the analgesic effects.28,56 Further, no affinity for dopamine, ben-
zodiazepine, opiate, central muscarinic or nicotinic receptors that 
have clinical relevance have been reported with flupirtine consist-
ent with the limited adverse effect profile.28
Flupirtine as a treatment of fibromyalgia
Evidence of effectiveness of flupirtine for the treatment of fibro-
myalgia is lacking with only one published open-label case study. 
A reduction of the symptoms of fibromyalgia following treatment 
with flupirtine was reported in the open-label case study,43 sug-
gesting a viable therapeutic approach (Table 1).
Having used flupirtine as an adjunct for patients with fibromy-
algia in our practice, an observational audit of 14 patients offered 
the medication as a treatment option is presented in Table 2. Fi-
bromyalgia was the sole condition for flupirtine use and diagnosis 
was made by patients meeting the ACR Diagnostic Criteria for Fi-
bromyalgia 2010 and the absence of a possible cause noted from 
blood results and radiological imaging. The assessment of effec-
tiveness was based on the patient perspective identified on co-ad-
ministration of flupirtine with their current therapies. Benefit was 
reported throughout the period of flupirtine treatment which was 
the only common medication administered to all the subjects. The 
mean age of the patients was 53 (range: 27–72) years, of which 
11 were female and three were male. Treatment duration ranged 
between 210 and 1,626 days up to the implementation of the Eu-
ropean Medicine Agency’s withdrawal of flupirtine-containing 
medications.28 Dosages of flupirtine were variable (200–600 mg/
day), with 100 mg at four times daily a common regimen and 50% 
of patients prescribed up to 600 mg within 24 hours. All patients 
reported ‘improvement’ in their symptoms following flupirtine 
treatment. This was self-reported, and despite the lack of numeri-
cal quantification, their persistence (up to 1,626 days) in continu-
ing flupirtine treatment was consistent with a benefit in symptoms 
being gained. Thirteen patients reported an improved control of 
their symptoms with 50% of the cohort reporting a ‘significant’ to 
‘excellent’ improvement. No significant adverse effects were re-
ported and raised LFTs were not observed, even though 12 patients 
used flupirtine for 750 days or greater and eight of those patients 
had received treatment for more than 1,000 days continuously. Al-
though numbers of patients in this observational audit were low, 
considering the higher dosages administered to and the duration 
of use (2–4.5 years) by the majority of the patients, the complica-
tions (rare serious liver injury) concerning the European Medicine 
Agency’s withdrawal of flupirtine-containing products were not 
evident. These findings support a controlled study to evaluate flu-
pirtine treatment in patients with fibromyalgia who are identified 
as flupirtine responders.
Relevance of flupirtine to fibromyalgia
Flupirtine controlling the symptoms of fibromyalgia, particularly 
pain, is suggested from the included observational audit which 
is consistent with the observations of Stoll.43 Thus, activation of 
Kv7 channels in nociceptive pathways by flupirtine evokes anal-
gesic benefit to patients with fibromyalgia.57 Kv7 channels have 
also been identified in nodose ganglion cells where nerve fibres 
involved in visceral perception in the respiratory organs, gastroin-
testinal organs and heart originate.58 Thus, the action of flupirtine 
on Kv7 channels, which regulate the sensitivity of visceral sensory 
neurons to noxious chemical and mechanical stimuli in humans,59 
represent an additional property for the management of patholo-
gies which can occur as comorbidities in fibromyalgia. NMDA 
receptor-mediated spinal mono- and poly-synaptic reflexes were 
attenuated in humans by flupirtine being treated with a 400 mg 
oral dose, suppressing rigidity in skeletal muscle and subsequent 
akinesia.60,61 The skeletal muscle relaxant and analgesic properties 
of flupirtine are demonstrated in the same dose range, and thus 
would be applicable in the treatment of fibromyalgia.
Reductions in gray matter volume, particularly in the anterior 
cingulate cortex, the prefrontal cortex and the insula areas of the 
brain, are consistently observed in patients with fibromyalgia.62 
The atrophy in pain-related brain areas in fibromyalgia has been 
suggested to contribute to some of the symptoms.63 Flupirtine has 
been reported to exhibit neuro-protective activity in a variety of 
neurodegenerative disease models due to indirect antagonism of 
NMDA receptors, upregulation of the anti-apoptotic protein B-
cell lymphoma 2 (Bcl2) and antioxidant activity via increased 
glutathione levels.64–67 These effects are suggested to be due to 
mechanisms such as prevention of intracellular calcium overload 
and oxidative stress reduction associated with the analgesic prop-
erties of flupirtine.
Potential limitations of flupirtine
Mild increases in liver enzymes, bilirubin and creatinine have been 
observed in some patients, but are usually not viewed significant 
enough to interrupt treatment.68 Flupirtine has however been asso-
ciated with very rare cases of severe drug-induced liver injury due 
to hepatotoxic metabolites.69,70 The incidence of flupirtine-related 
hepatobiliary adverse events in the BfArM database was estimated 
to be about eight in 100,000 patients (>0.01%).71 The reactive me-
tabolites responsible for liver injury are detoxified via glutathione 
and thus, sufficient cellular glutathione stores will limit hepato-
toxicity.70
The European Medicines Agency’s Pharmacovigilance Risk 
Assessment committee recommended risk minimization measures 
(RMM) for flupirtine (use only after other analgesics were trialled, 
patients restricted to up to two week-long treatments, with weekly 
LFT) due to concern of rare serious liver injury associated with 
long-term use of flupirtine.28 Limited adherence to the RMM led 
to withdrawal of flupirtine-containing medications from the Euro-
pean market in 2018.28 Serious liver injury, however, was not seen 
as a complication in the studies discussed above.
Future directions
The complex heterogenous disorder fibromyalgia is currently 
medically unmet with limited benefit gained from available thera-
pies. The diversity of the symptoms of fibromyalgia and the related 
physiology suggests that to achieve effective therapeutic control 
drug treatments need to target multiple events, which has led to 
combination therapy as a standard approach. Kv7 channel activa-
tion alone or in combination with other pharmacological mecha-
nisms of action, as exemplified by flupirtine, appears to exhibit a 
spectrum of pharmacology beneficial to patients with fibromyal-
gia that responded to this treatment. Development of novel Kv7 
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channel activators has gained interest, which could offer additional 
approaches for the management of complex clinical conditions.72 
Thus, investigation in patient responders of the efficacy of flupir-
tine, or related drugs exhibiting a similar pharmacology, as a treat-
ment approach would be of interest.
Conclusion
Flupirtine, an indirect NMDA receptor antagonist due to Kv7 
channel activation and GABAA receptor agonism, is a novel an-
algesic medication with utility in the treatment of patients with 
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